Skip to main content

Table 2 Plasma or serum lipid profiles in control subjects and patients whose HDL antioxidative activities were measured in apoBd plasma or serum, respectively, with the DCF assay

From: Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins

  Plasma Serum
Controls CHD High TG High SAA Controls High MPO
Number 59 58 37 28 57 30
M/F, n 30/29 54/4** 25/12 19/9 32/25 15/15
TC, mg/dL 165 ± 26 145 ± 29** 262 ± 178** 163 ± 44 188 ± 38 169 ± 46
HDL-C, mg/dL 59 ± 14 43 ± 13** 34 ± 15** 51 ± 17* 60 ± 15 49 ± 16*
LDL-C, mg/dL 94 ± 19 80 ± 23** 115 ± 68* 89 ± 6 112 ± 35 100 ± 41
TG, mg/dL 74 (63–99) 128 (88–170)** 324 (264–1080)** 115 (92–163)* 97 (70–123) 116 (93–146)
sd LDL-C, mg/dL 16 (14–19) 37 (27–44)** 41 (27–63)** 17 (12–27) 25 (18–32) 23 (19–30)
Apo A-I, mg/dL 158 ± 23 152 ± 34 129 ± 45** 148 ± 48 168 ± 29 149 ± 33
Glucose, mg/dL 110 ± 17 103 ± 31 164 ± 80 110 ± 21 92 ± 15 105 ± 23
Insulin μIU/mL 13.2 ± 13.1 15.1 ± 9.5 19.8 ± 12.1 14.1 ± 7.2 8.3 ± 5.1 22.0 ± 13.5
Hs-CRP, mg/L 1.7 ± 1.9 2.4 ± 4.9 7.9 ± 15.1 5.5 ± 4.4 1.3 ± 1.2 2.7 ± 11.6
HDL distribution
 Preβ-1, % 8 (6–10) 12 (9–15)** 15 (10–19)** 8 (6–11) 5 (4–7) 5 (4–7)
 α-1, % 23 (20–28) 15 (12–19)** 11 (7–17)** 17 (12–21)** 22 (19–25) 20 (16–22)
 α-2, % 44 (42–47) 42 (39–45)* 41 (36–44)* 54 (49–61)** 41 (37–44) 40 (39–43)
 α-3, % 15 (13–16) 18 (16–20)** 17 (13–23)** 11 (9–15)** 13 (12–15) 15 (13–17)
 α-4, % 10 (8–11) 12 (10–14)** 13 (10–16)** 6 (5–9)** 11 (9–12) 12 (10–14)
  1. Data are shown as mean ± SD or median (interquartile range). Differences in values between each group and Controls were tested by Pearson chi-squared test, Student-t test or Mann-Whitney’s U test (*p < 0.05 and **p < 0.01, relative to Controls)